Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer

Status Recruiting

Clinical Trial Summary

To investigate the response of temozolomide versus prophylactic cranial radiotherapy in preventing brain metastases in completed or partial remission limited small cell lung cancer patients.

Clinical Trial Description

We'd like to investigate the 2-year incidence rate of brain metastases in completed or partial remission limited small cell lung cancer patients who received temozolomide only for 12 months or 25-30Gy prophylactic cranial radiotherapy in preventing brain metastases. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02605811
Study type	Interventional
Source	Guangzhou Medical University
Contact	Haihong Yang, MD
Phone	862083062825
Email	bjrf2009@yahoo.com
Status	Recruiting
Phase	Phase 2
Start date	September 2015
Completion date	December 2021

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03651219` - Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer	Phase 3
Active, not recruiting	`NCT03958045` - Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma	Phase 2
Active, not recruiting	`NCT04885998` - AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)	Phase 1
Active, not recruiting	`NCT03703297` - Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy	Phase 3
Recruiting	`NCT05903092` - MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer	Phase 2
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Terminated	`NCT04422210` - A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).	Phase 1
Not yet recruiting	`NCT02875457` - Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin	Phase 3
Recruiting	`NCT02577627` - Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC	N/A
Completed	`NCT02551432` - Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer	Phase 2
Withdrawn	`NCT02542137` - Abscopal Effect for Metastatic Small Cell Lung Cancer	Phase 2
Recruiting	`NCT02262897` - The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer	Phase 2
Terminated	`NCT00969306` - Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients	Phase 1
Completed	`NCT01831089` - Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors	Phase 1
Completed	`NCT01943578` - Value of Physical Capacity Tests in Lung Cancer	N/A
Completed	`NCT01497873` - A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer	Phase 2
Terminated	`NCT00958022` - Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer	Phase 1
Completed	`NCT00930891` - Bevacizumab in Extensive Small Cell Lung Cancer	Phase 2/Phase 3
Terminated	`NCT00702962` - Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer	Phase 1/Phase 2
Recruiting	`NCT00686985` - Docetaxel - Carboplatin as Second Line Treatment in Patients With Small Cell Lung Cancer	Phase 2